Challenges in the discovery and development of new agents for the treatment of obesity.

Staten, M A

Staten, M A.

Afiliación

Staten MA; Division of Diabetes and Kidney and Digestive Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. statenm@niddk.nih.gov

Clin Pharmacol Ther ; 81(5): 753-5, 2007 May.

Article en En | MEDLINE | ID: mdl-17377527

RESUMEN

New pharmacologic agents are being sought to help manage the epidemic of obesity and its consequences. Understanding the challenges of the history of obesity drugs is wise before investing in new obesity agents. Expectations of patients, physicians, and drug company executives are not consistent with characteristics of current agents or most potential new ones. Owing to the complex biology underlying body weight regulation, combinations of agents may be necessary to improve weight loss efficacy.

Asunto(s)

Fármacos Antiobesidad/uso terapéutico; Obesidad/tratamiento farmacológico; Animales; Fármacos Antiobesidad/historia; Ensayos Clínicos como Asunto; Diseño de Fármacos; Historia del Siglo XX; Humanos; Obesidad/genética; Obesidad/fisiopatología

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Antiobesidad / Obesidad Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Clin Pharmacol Ther Año: 2007 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links